Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Cancer|Gastric Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer Metastatic|Colo-rectal Cancer|Solid Tumor|Solid Carcinoma|Solid Carcinoma of Stomach|Cancer of Stomach|Lymphoma|Sarcoma|Cutaneous T Cell Lymphoma|Head and Neck Squamous Cell Carcinoma|Basal Cell Carcinoma|Cutaneous T-cell Lymphoma|Cutaneous Squamous Cell Carcinoma
Interventions: DRUG: GZ17-6.02|DRUG: Capecitabine
Sponsor: Genzada Pharmaceuticals USA, Inc.
Collaborators: Translational Drug Development